EUVIMEDEUVIMED entdecken
Crossref

Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia

The Brown University Psychopharmacology Update · 2026-03 · 37 (3) · 1-5

DOI: 10.1002/pu.31414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 23.02.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Weekly injections of semaglutide over 26 weeks were more effective than matching placebo in improving glycemic control and weight outcomes in patients with schizophrenia who received clozapine or olanzapine, a randomized trial has found. Participants receiving semaglutide did not experience a disproportionate number of adverse events. Study results were published online Dec. 3, 2025 in JAMA Psychiatry .

Zitieren

APA

(2026). Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia. The Brown University Psychopharmacology Update, 37(3), 1-5. https://doi.org/10.1002/pu.31414

Vancouver

Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia. The Brown University Psychopharmacology Update. 2026;37(3):1-5. doi:10.1002/pu.31414

BibTeX
@article{euvimed2026,
  title = {Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {3},
  pages = {1--5},
  doi = {10.1002/pu.31414}
}
Kostenlos starten →